When Innovation And Access Diverge: Who Pays For India's First Dengue Vaccine?

A Vaccine That Exists Is Not The Same As A Vaccine That Reaches People

India now has its first dengue vaccine. That sentence alone sounds like unambiguous good news - and in one sense, it is. But the story of Qdenga's approval is really two stories running in parallel: the genuine scientific achievement of building a vaccine against four distinct dengue serotypes and the much older, much more familiar problem of whether that achievement will actually help the people who need it most.

Why This Vaccine Took So Long To Build Dengue is

unusually hard to vaccinate against because there isn't one virus to defend against - there are four antigenically distinct serotypes. Worse, a second infection by a different serotype can trigger antibody-dependent enhancement, making the disease more severe, not less.

This is precisely what went wrong with the world's first dengue vaccine, Dengvaxia, in the Philippines in 2017, when dengue-naive children who received it faced a higher risk of severe illness. Qdenga's design, unlike Dengvaxia's, doesn't require screening people for prior infection before vaccinating them - a genuine technical advance that took Takeda years and enormous R&D investment to achieve.

The Access Problem Hiding Inside The Good News That

R&D cost is exactly why Takeda follows a tiered global pricing model - charging more in wealthier markets to subsidise access elsewhere. In principle, that's a reasonable way to fund complex vaccine science. In practice, in India, it risks pricing Qdenga out of reach for the dense urban slums with poor drainage and the highly mobile migrant workforce who are, by a wide margin, the population most exposed to Aedes mosquitoes in the first place.

The Two-Dose Problem Makes This Worse

Qdenga needs two doses three months apart and its protection varies by serotype - strongest against DENV-2, weaker and less certain against DENV-3, whose prevalence is rising in India. A migrant worker who gets dose one in June and moves cities before September, when dose two is due, may end up only partially protected against exactly the serotype now becoming more common.

Access and completion aren't separate problems from affordability - they compound it. A vaccine that's too expensive to reach slum populations is also a vaccine whose second dose is hardest to track down for the same population.

What Needs To Happen Next None of

this is an argument against Qdenga's approval - CDSCO's decision reflects genuine, WHO-backed evidence that the vaccine works. The argument is about what happens between approval and actual protection on the ground. If the government does not negotiate a lower price and build a distribution plan specifically designed for slum and migrant populations, Qdenga's public health impact could be concentrated almost entirely among people who were already at lower relative risk.

The rollout, not the approval, is where this story will actually be decided - and right now, nothing prevents Qdenga's benefit from being captured overwhelmingly by those who could always have paid for protection anyway.